Article Text

Download PDFPDF
The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic
  1. Daniele Leonardi Vinci1,
  2. Adriano Meccio2,
  3. Alessio Provenzani3,
  4. Maria Ernestina Faggiano4,
  5. Nenad Miljković5,
  6. Despina Makridaki6,
  7. Petr Horák7,
  8. Piera Polidori3
  1. 1 School of Specialization in Hospital Pharmacy, University of Palermo, Palermo, Sicilia, Italy
  2. 2 Chemical Engineering, University of Palermo, Palermo, Sicilia, Italy
  3. 3 Clinical Pharmacy, ISMETT, Palermo, Italy
  4. 4 Pharmacy, AOU Policlinico, Bari, Puglia, Italy
  5. 5 Hospital Pharmacy, Institute of Orthopaedic Surgery "Banjica", Belgrade, Serbia
  6. 6 Pharmacy Services, "Sismanoglio- Amalia Fleming", General Hospital of Attica, Athens, Greece
  7. 7 Hospital Pharmacy, Motol University Hospital, Praha, Praha, Czech Republic
  1. Correspondence to Dr Daniele Leonardi Vinci, School of Specialization in Hospital Pharmacy, University of Palermo, Palermo 90131, Italy; daniele.leo93{at}gmail.com

Abstract

Objective To create an informatics supportive tool, which can assist healthcare professionals in estimating potential requirements for essential drug supplies to respond to the current SARS-CoV-2 pandemic based on epidemiological forecasting.

Methods The tool was based on a Susceptible-Infected-Removed (SIR) epidemiological model in which the population is divided into three compartments and transmission parameters are specified to define the rate at which people move between stages. Appropriate data entry was guaranteed by the creation of structured guided paths. The drugs needed for the forecasted patients were estimated according to a list of critical care drugs compiled by consulting previous published scientific works, national and international guidelines. For each drug, an estimation was made of the percentage average ICU uptake for each therapeutic group and active principle.

Results The tool consists of a Microsoft Excel template that is based on the initial epidemiological situation, the non-pharmaceutical interventions applied, the risk of hospitalisation based on the population age distribution, and the hospital beds available. The tool provides a forecast of which patients with COVID-19 will need to be treated in a hospital setting. The number of patients is used to estimate the drugs needed based on the average daily dose and the treatment length of each drug. The possibility of editing the type of distribution (exponential or linear) of the number of patients at the beginning of the analysis, the percentage adherence with non-pharmaceutical interventions and their delayed effect, and all the key epidemiological parameters make the estimation tailorable to different clinical contexts and needs.

Conclusions This model might be an effective supporting tool that could be easily implemented within the workflow of health professionals. All the information reported in this paper could be useful in developing new strategies to tackle the COVID-19 pandemic.

  • public health
  • critical care
  • COVID-19
  • practice guideline
  • health care rationing
  • health care economics and organizations
  • Medical Informatics
  • CLINICAL MEDICINE

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. No patients data included.

This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. No patients data included.

View Full Text